Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Sarepta Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $653.10M, down 53.2% year over year. For fiscal 2025 it was $1.52B, up 89.2% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $1.52B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52B | +89.2% |
| FY2024 | Dec 31, 2024 | $804.52M | -8.3% |
| FY2023 | Dec 31, 2023 | $877.39M | +0.0% |
| FY2022 | Dec 31, 2022 | $877.09M | +13.7% |
| FY2021 | Dec 31, 2021 | $771.18M | +6.8% |
| FY2020 | Dec 31, 2020 | $722.34M | +28.8% |
| FY2019 | Dec 31, 2019 | $560.91M | +39.6% |
| FY2018 | Dec 31, 2018 | $401.84M | +141.0% |
| FY2017 | Dec 31, 2017 | $166.71M | -11.5% |
| FY2016 | Dec 31, 2016 | $188.27M | +28.6% |
| FY2015 | Dec 31, 2015 | $146.39M | +55.4% |
| FY2014 | Dec 31, 2014 | $94.23M | +29.2% |
| FY2013 | Dec 31, 2013 | $72.91M | +39.1% |
| FY2012 | Dec 31, 2012 | $52.40M | -21.6% |
| FY2011 | Dec 31, 2011 | $66.86M | +85.9% |
| FY2010 | Dec 31, 2010 | $35.97M | +47.5% |
| FY2009 | Dec 31, 2009 | $24.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $82.55M | -62.3% |
| Q2 FY2026 | Jun 30, 2026 | $91.26M | -55.4% |
| Q1 FY2026 | Mar 31, 2026 | $153.96M | -80.1% |
| Q4 FY2025 | Dec 31, 2025 | $325.34M | +62.7% |
| Q3 FY2025 | Sep 30, 2025 | $218.89M | -2.5% |
| Q2 FY2025 | Jun 30, 2025 | $204.39M | +13.7% |
| Q1 FY2025 | Mar 31, 2025 | $773.45M | +286.0% |
| Q4 FY2024 | Dec 31, 2024 | $199.95M | +2.3% |
| Q3 FY2024 | Sep 30, 2024 | $224.48M | +15.5% |
| Q2 FY2024 | Jun 30, 2024 | $179.69M | -25.7% |
| Q1 FY2024 | Mar 31, 2024 | $200.40M | -18.4% |
| Q4 FY2023 | Dec 31, 2023 | $195.52M | -8.6% |
| Q3 FY2023 | Sep 30, 2023 | $194.30M | -10.3% |
| Q2 FY2023 | Jun 30, 2023 | $241.89M | -4.1% |
| Q1 FY2023 | Mar 31, 2023 | $245.68M | +26.5% |
| Q4 FY2022 | Dec 31, 2022 | $213.80M | +8.4% |
| Q3 FY2022 | Sep 30, 2022 | $216.71M | +55.8% |
| Q2 FY2022 | Jun 30, 2022 | $252.33M | +5.3% |
| Q1 FY2022 | Mar 31, 2022 | $194.25M | -0.5% |
| Q4 FY2021 | Dec 31, 2021 | $197.30M | -4.8% |
| Q3 FY2021 | Sep 30, 2021 | $139.12M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $239.62M | +27.1% |
| Q1 FY2021 | Mar 31, 2021 | $195.15M | +43.3% |
| Q4 FY2020 | Dec 31, 2020 | $207.24M | -7.1% |
| Q3 FY2020 | Sep 30, 2020 | $190.44M | +42.2% |
| Q2 FY2020 | Jun 30, 2020 | $188.52M | +66.4% |
| Q1 FY2020 | Mar 31, 2020 | $136.14M | +50.3% |
| Q4 FY2019 | Dec 31, 2019 | $223.14M | +52.6% |
| Q3 FY2019 | Sep 30, 2019 | $133.95M | +54.7% |
| Q2 FY2019 | Jun 30, 2019 | $113.27M | -7.8% |
| Q1 FY2019 | Mar 31, 2019 | $90.55M | +96.0% |
| Q4 FY2018 | Dec 31, 2018 | $146.21M | +229.0% |
| Q3 FY2018 | Sep 30, 2018 | $86.58M | +152.9% |
| Q2 FY2018 | Jun 30, 2018 | $122.85M | +108.5% |
| Q1 FY2018 | Mar 31, 2018 | $46.20M | +58.7% |
| Q4 FY2017 | Dec 31, 2017 | $44.44M | -37.2% |
| Q3 FY2017 | Sep 30, 2017 | $34.24M | – |
| Q2 FY2017 | Jun 30, 2017 | $58.91M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $70.75M | – |
See a number that looks wrong?